PROGEN Stock Overview
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Prostatype Genomics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.20 |
| 52 Week High | SEK 240.00 |
| 52 Week Low | SEK 7.55 |
| Beta | 0.69 |
| 11 Month Change | -36.92% |
| 3 Month Change | -34.40% |
| 1 Year Change | -90.21% |
| 33 Year Change | -99.92% |
| 5 Year Change | n/a |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| PROGEN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.5% | -0.5% | -0.2% |
| 1Y | -90.2% | 14.3% | 11.8% |
Return vs Industry: PROGEN underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: PROGEN underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| PROGEN volatility | |
|---|---|
| PROGEN Average Weekly Movement | 17.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: PROGEN's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: PROGEN's weekly volatility has decreased from 25% to 18% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 6 | Fredrik Rickman | www.prostatypegenomics.com |
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company’s test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision.
Prostatype Genomics AB (publ) Fundamentals Summary
| PROGEN fundamental statistics | |
|---|---|
| Market cap | SEK 8.12m |
| Earnings (TTM) | -SEK 40.54m |
| Revenue (TTM) | SEK 4.12m |
2.0x
P/S Ratio-0.2x
P/E RatioIs PROGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROGEN income statement (TTM) | |
|---|---|
| Revenue | SEK 4.12m |
| Cost of Revenue | SEK 20.11m |
| Gross Profit | -SEK 16.00m |
| Other Expenses | SEK 24.54m |
| Earnings | -SEK 40.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -40.92 |
| Gross Margin | -388.80% |
| Net Profit Margin | -985.22% |
| Debt/Equity Ratio | 0% |
How did PROGEN perform over the long term?
See historical performance and comparison